This is a type of cancer called myeloma that grows very slowly. It doesn't usually cause symptoms right away. It's a less severe form of myeloma, but it can turn into the more serious form if not treated.
Every report comes from a Lived member, sent anonymously.
Have you tried Watchful Waiting for Smoldering Multiple Myeloma?
Smoldering multiple myeloma is an early, symptom-free stage on the path to multiple myeloma, a cancer of plasma cells. Plasma cells are white blood cells in the bone marrow that make antibodies. In smoldering myeloma, one abnormal group of plasma cells has grown large enough to meet the laboratory definition of myeloma, but it has not yet harmed the bones, kidneys or blood counts. Because it causes no symptoms, it is usually found by chance, when a blood or urine test done for another reason shows an unusual protein. The condition matters because it can progress to active myeloma, which does need treatment. Some people stay stable for many years, while others progress within a year or two, so much of the care is about estimating which path someone is on. Smoldering myeloma sits between two related conditions. Monoclonal gammopathy of undetermined significance (MGUS) is a milder precursor with fewer abnormal cells and a much lower chance of progressing. Active multiple myeloma is the stage at which the disease causes damage or reaches thresholds that predict damage soon.
Smoldering myeloma has no known trigger, and nothing a person did is known to cause it. It begins when a single plasma cell acquires genetic changes and multiplies into a clone. Myeloma is almost always preceded by MGUS, which often goes unnoticed for years. The same factors linked to multiple myeloma raise the likelihood of these precursor conditions. Risk rises with age, and myeloma is more common in men and in Black people. A personal history of MGUS is a risk factor, and exposure to radiation or certain chemicals has also been linked to myeloma. These are associations, not causes, and most people with them never develop the disease.
The first clue is usually monoclonal protein, or M protein: a single type of antibody made in excess by the abnormal plasma cells. It is measured in the blood in grams per deciliter (g/dL) and can also appear in urine. A related blood test measures free light chains, small antibody fragments, and compares the abnormal type with the normal type as a ratio. A bone marrow biopsy, in which a small sample is taken with a needle, usually from the hip bone, shows what percentage of marrow cells are abnormal plasma cells. Smoldering myeloma is diagnosed when the M protein in the blood is 3 g/dL or more (or there is a significant amount in urine), or abnormal plasma cells make up 10% to 60% of the marrow, and there are no signs of damage. Below these levels the diagnosis is usually MGUS. The rest of the evaluation looks for anything that would mean active myeloma instead. Blood tests check calcium, kidney function and hemoglobin (anemia), and imaging such as CT, PET-CT or MRI looks for bone lesions. Very high marrow involvement (60% or more), a light chain ratio of 100 or more, or more than one spot on MRI also count as active myeloma, because they predict damage soon. Doctors then estimate risk. A widely used model, known as 2/20/20, counts three features: M protein above 2 g/dL, a free light chain ratio above 20, and marrow plasma cells above 20%. Having two or more points to high-risk disease, in which close to half of people progress within two years. Genetic tests on the marrow cells can refine this estimate.
Smoldering myeloma does not cause harm by itself, so the main question is whether treating early to delay active myeloma is worth the side effects and time on therapy. For people at low or intermediate risk, the usual approach is careful observation, sometimes called active monitoring: no cancer treatment, but regular testing so that progression is caught before it damages bones or kidneys. For high-risk disease, there is now an approved option. Daratumumab is an antibody drug that targets a protein (CD38) on plasma cells and helps the immune system destroy them. Its under-the-skin form, Darzalex Faspro, is approved in the United States for high-risk smoldering myeloma, given as an injection weekly at first and then less often, for up to three years. In the main trial, it cut the risk of progressing to active myeloma by about half compared with monitoring. It has not clearly been shown to help people live longer, and it does not cure the disease, so some specialists still offer monitoring to high-risk patients and decide together with them. The trade-offs are real. Daratumumab can cause reactions during or after the injection, upper respiratory infections, fatigue, diarrhea and rash, and it can lead to serious infections. It is not approved for lower-risk disease, where most people would be treated without benefit. Lenalidomide, an oral drug used in myeloma, also delayed progression in a trial but caused significant side effects in about a quarter of people and is not approved for this use. Clinical trials are testing more intensive approaches, including newer immune therapies, aimed at deeper and longer-lasting control.
For most people, daily life does not change. Smoldering myeloma causes no symptoms, so the main experience is regular appointments and the uncertainty of living with a condition that may or may not progress. That waiting can weigh on people, and it is worth talking about. The chance of progression is highest in the first years after diagnosis. In a long-term study, about 10% of people per year progressed to active myeloma during the first five years, about 3% per year over the next five, and about 1% per year after that. An individual's risk depends heavily on their risk group, and many people never progress. Monitoring usually means blood and urine tests about 2 to 3 months after diagnosis, then every 4 to 6 months for the first year, and every 6 to 12 months if things stay stable, with imaging repeated as needed. A rising M protein, rising light chains or a falling hemoglobin can signal change. With this kind of follow-up, progression is usually caught on tests before it causes lasting damage, and active myeloma has many effective treatments when it is needed.
Keep scheduled monitoring appointments even when you feel well, since tests usually detect change before symptoms do. Contact your care team if you develop symptoms that can signal active myeloma: new or worsening bone pain (often in the back or ribs), a bone that breaks with little force, frequent infections or unexplained fevers, unusual tiredness or weakness, or strong thirst with frequent urination or new confusion, which can reflect high calcium. If you are receiving daratumumab, contact the team promptly about a fever or signs of infection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Smoldering Multiple Myeloma is like, what's helped you, or ask the community a question.